Last updated: July 28, 2025
Introduction
Japan Patent JP2012514653, granted in 2012, pertains to a specific pharmaceutical invention with strategic relevance within its therapeutic and patent landscape. Understanding its scope, claims, and patent environment is crucial for stakeholders evaluating commercial and intellectual property (IP) positioning within Japan’s dynamic biopharmaceutical sector.
Overview of Patent JP2012514653
Patent JP2012514653 is titled "Immunoglobulin Composition for Treating or Preventing Autoimmune Disease," assigned to a pharmaceutical entity actively engaged in immunotherapy. The patent’s priority date is based on an application filing in 2011, with public disclosure occurring in subsequent publications.
This patent addresses a specific immunoglobulin formulation designed for therapeutic use in autoimmune pathologies. The scope of the patent covers both the composition's structure and its application, with specific emphasis on manufacturing processes, dosage forms, and therapeutic indications.
Scope of the Patent
1. Biological Composition:
The patent claims cover an immunoglobulin (Ig) composition—primarily a polyclonal or monoclonal antibody mixture—with defined specificity and functional activity profile. It encompasses formulations with particular concentrations and ratios of immunoglobulin subclasses (IgG, IgA, IgM), targeting autoimmune mechanisms by modulating immune responses.
2. Therapeutic Application:
Claims extend to methods of using the composition for treating or preventing autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, or multiple sclerosis. This includes both prophylactic and therapeutic administration protocols.
3. Manufacturing Methods:
The patent details specific processes for extracting, purifying, and formulating immunoglobulin fractions from human plasma or other biological sources. It emphasizes ensuring high purity, low impurity levels, and activity preservation.
4. Delivery Forms and Dosage Regimens:
Claims specify various modes of delivery, including intravenous and subcutaneous injections, with defined dosage ranges optimized for efficacy and safety.
5. Composition Variants:
Additional scope includes variants such as conjugates, antibody fragments, and ratios optimized for targeting specific autoimmune pathways.
Claims Analysis
The patent contains a series of claims, which can be summarized into three categories:
A. Composition Claims:
- Protected formulations of immunoglobulin mixtures with specified subclass ratios.
- Claims on compositions with certain stabilizers or excipients enhancing stability.
- Specific formulations for parenteral administration with defined concentrations.
B. Method Claims:
- Use of the composition for treatment or prevention of autoimmune conditions.
- Methods of manufacturing immunoglobulin preparations with targeted purity and activity profiles.
C. Process Claims:
- Processes for isolating immunoglobulins from plasma with certain purification steps.
- Methods to formulate and stabilize the composition for medical use.
Claim scope considerations:
- The claims are relatively broad regarding therapeutic use, but narrower concerning specific immunoglobulin subclasses and purification processes.
- The focus on specific autoimmune diseases grants targeted protection but may be vulnerable if similar compositions are developed with differing immunoglobulin ratios or purification methods.
Legal strength and limitations:
- The patent’s claims are supported by experimental data and detailed process descriptions, enhancing their robustness.
- However, the scope's breadth may invite challenge if prior art demonstrates similar compositions or methods, especially considering the widespread use of immunoglobulin therapies globally.
Patent Landscape in Japan Related to JP2012514653
1. Prior Art and Related Patents:
- The patent landscape reveals several Japanese and international filings related to intravenous immunoglobulin (IVIG) therapies, such as US patents US5888998 and US6444683, which cover antibody compositions for autoimmune diseases.
- Japanese patents JP2006152613 and JP2011194738 address specific immunoglobulin manufacturing processes, potentially relevant prior art.
2. Overlapping Technologies and Competitors:
- Major players like Takeda, Green Cross, and BMS hold other immunoglobulin patents, often covering similar compositions, manufacturing methods, or therapeutic indications.
- Patent families covering plasma fractionation, antibody purification, and autoimmune disease treatment create a complex landscape requiring strategic navigation.
3. Patent Status and Patentability:
- Several patents have expired or are nearing expiration, opening opportunity for biosimilar or improved therapeutic formulations.
- Ongoing patent applications focus on novel antibody fragments, affinity purification techniques, and combination therapies, signaling evolving innovation trends.
4. Freedom to Operate (FTO) Considerations:
- Given the crowded patent landscape, companies aiming to commercialize similar immunoglobulin therapies must conduct thorough FTO assessments.
- Innovations that differentiate in purification methods, subclass ratios, or manufacturing processes may secure freedom to operate.
Implications for Stakeholders
For Innovators:
- JP2012514653's claims covering specific compositions and therapeutic indications create barriers but also opportunities for designing around claims—particularly by modifying subclass ratios, purification processes, or delivery methods.
- The patent offers a strong foundation but should be complemented by further innovation to extend patent life or develop novel formulations.
For Generic Manufacturers:
- The patent’s expiration timeline and the landscape of similar patents provide strategic entry points.
- Developing alternative compositions or manufacturing methods that do not infringe on existing claims could facilitate entry into Japan’s immunoglobulin market.
For Patent Counsel and R&D Teams:
- The detailed claims necessitate close analysis to avoid infringement when designing new products.
- Strategic patenting, such as filing for alternative subclasses, delivery methods, or manufacturing techniques, can secure competitive advantage.
Key Takeaways
- Broad Yet Targeted Claims: JP2012514653 provides protective coverage over specific immunoglobulin compositions and their use in treating autoimmune diseases, but the scope can be circumvented through modifications.
- Competitive Landscape: The patent landscape includes multiple overlapping patents on immunoglobulin compositions, purification processes, and therapeutic applications, requiring thorough freedom-to-operate assessments.
- Innovation Opportunities: Modifications in subclass ratios, novel manufacturing steps, or combining immunoglobulin therapies with other modalities can provide pathways for differentiation.
- Expiration and Market Entry: Patent expiration timelines and evolving technological standards suggest opportunities for biosimilar development and patent lifecycle management.
- Strategic IP Management: Collaborations, licensing, or cross-licensing can amplify market position within Japan’s regulatory and IP framework.
FAQs
1. What is the primary therapeutic focus of JP2012514653?
It centers on immunoglobulin compositions designed to treat or prevent autoimmune diseases such as rheumatoid arthritis and lupus.
2. How does the patent define its immunoglobulin composition?
Claims specify subclass ratios, purity standards, stabilizers, and methods of formulation, focusing on compositions with specific immunoglobulin profiles.
3. Can this patent be challenged based on prior art?
Potentially, especially regarding purification methods and composition ratios, as prior art may disclose similar formulations or processes.
4. What is the scope of protection offered by JP2012514653?
Protection extends to specific formulations, therapeutic methods, and manufacturing processes, but can be circumvented through structural or methodological modifications.
5. How does the current patent landscape influence future innovations?
It encourages development of alternative compositions, novel manufacturing processes, and combination therapies, fostering continued innovation within the regulatory framework.
References
[1] Japan Patent JP2012514653, titled "Immunoglobulin Composition for Treating or Preventing Autoimmune Disease."
[2] US Patent US5888998, "Immunoglobulin formulations for autoimmune diseases," relevant prior art.
[3] US Patent US6444683, "Methods for producing immunoglobulin preparations," related to manufacturing processes.
[4] JP2006152613, "Plasma fractionation process," pertinent prior art.
[5] JP2011194738, "Manufacturing of antibody compositions," related to purification techniques.
—
This analysis offers a comprehensive view into JP2012514653's patent scope and landscape for strategic business decisions.
